Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Decreased cravings for pleasure may be at root of a core symptom of major depressive disorder

Decreased motivation to seek and experience pleasurable experiences, known as anhedonia, is a primary symptom of major depressive disorder. Anhedonia is less responsive to many antidepressants and often persists after other symptoms of depression subside. However, understanding the different components of anhedonia - the desire to obtain something pleasurable versus experiencing pleasure - has been difficult for researchers to determine in humans.

12 Aug 2009

Depression among preschoolers - may continue into childhood

Depression among preschoolers appears to be a continuous, chronic condition rather than a transient developmental stage, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Aug 2009

Depression missed and misidentified

A meta-analysis of more than 50,000 patients has shown that general practitioners (GPs) have great difficulty separating those with and without depression, with substantial numbers of missed and misidentified.

30 Jul 2009

Major depressive disorder redefined

Researchers from Rhode Island Hospital's department of psychiatry propose that the definition for major depressive disorder (MDD) should be shortened to include only the mood and cognitive symptoms that have been part of the definition in the Diagnostic and Statistical Manual of Mental Disorders (DSM) for the past 35 years.

24 Jul 2009

Light therapy as a treatment for sexual dysfunctions

Although we are still far from knowing exactly where and how the pineal suppressive role is exerted, the fact that the gland exerts an inhibitory function on the reproductive axis is widely accepted. In fact, the pineal seems to exert its hormonal effect at different levels of the reproductive axis, both at the hypothalamic-pituitary level and at the gonadal level, where melatonin receptors have also been found.

9 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Negative mood-related drinking may mean vulnerability for major depression and alcohol dependence

Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.

12 May 2009

Participants in antidepressant drug trials are atypical patients

One reason antidepressant medication treatments do not work as well in real life as they do in clinical studies could be the limited type of study participants selected, researchers at UT Southwestern Medical Center have found.

12 May 2009

GSK to divest U.S. rights for Wellbutrin XL to Biovail

GlaxoSmithKline has announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.

6 May 2009

Aussies wanted for international groundbreaking study on depression

Australians researchers have put out a call for 400 people to take part in a study on depression.

26 Apr 2009

In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression

Psychiatrists and critical care specialists at Johns Hopkins have begun to tease out what there is about a stay in an intensive care unit (ICU) that leads so many patients to report depression after they go home.

12 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

p11 protein may lead to faster acting antidepressants

Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

23 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Groundbreaking study into depression

Medical researchers from Sydney University's Brain Dynamics Centre have launched a world-first study that could lead to a dramatic improvement in how people are treated medically for depression.

19 Mar 2009

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Cephalon, Inc. has announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.

17 Mar 2009

Relationship between depressive symptoms and cardiac events

New data published in the March 17, 2009, issue of the Journal of the American College of Cardiology suggest that relatively healthy women with severe depression are at increased risk of cardiac events, including sudden cardiac death (SCD) and fatal coronary heart disease (CHD).

10 Mar 2009

History of major depression increases risk for heart disease more than genetics or environment

A history of major depression increases the risk of heart disease over and above any genetic risks common to depression and heart disease, according to researchers at Washington University School of Medicine in St. Louis and the VA.

4 Mar 2009

Transcendental meditation helps students with college stress

Transcendental meditation may be an effective non-medicinal tool for students to buffer themselves against the intense stresses of college life, according to a new study to be published in the February 24 issue of the peer-reviewed International Journal of Psychophysiology.

24 Feb 2009

Mum who tried to poison her children placed on good-behaviour bond

An Australian woman who tried to poison her two children last year has been placed on a good-behaviour bond after pleading guilty to the charge of intending to harm them.

10 Feb 2009